The results indicate that these targets are primarily associated with several signaling pathways, including the AGE‐RAGE signaling pathway in diabetic complications, fluid shear stress and atherosclerosis, lipid metabolism and atherosclerosis, IL‐17 signaling pathway, non‐alcoholic fatty liver disease, and so on (see Table 3). This evidence concerns the gene IL17A and metabolic dysfunction-associated steatotic liver disease.